Literature DB >> 19744175

Five-year experience in the treatment of alopecia areata with DPC.

B M El-Zawahry1, D A Bassiouny, A Khella, N S Zaki.   

Abstract

BACKGROUND: The effectiveness of Diphencyprone (DPC) in alopecia areata (AA) was demonstrated in several studies with highly variable response rates ranging from 5% to 85%.
OBJECTIVE: The response rate and variable factors affecting the prognosis were studied focusing on long-term follow-up with or without maintenance therapy.
METHODS: A total of 135 cases of AA were treated with DPC. Patients were divided into five groups according to the area of scalp affected: Grade 1 AA: 25-49% scalp affection; Grade 2 AA: 50-74% scalp affection; Grade 3 AA: 75-99% scalp affection; alopecia totalis and alopecia universalis. An initial response was defined as appearance of new terminal hair within treated sites. Excellent response was defined as terminal hair covering >75% of the scalp. Relapse meant >25% hair loss. Maintenance therapy meant ongoing therapy once every 1-4 weeks after excellent response. Follow-up was performed to detect any relapse of AA.
RESULTS: Ninety-seven patients continued therapy for >or=3 months. After an initial 3 month lag, cumulative excellent response was seen in 15 patients (15.4%), 47 patients (48.5%), 51 patients (52.6%) and 55 patients (55.7%) after 6, 12, 18 and 24 months respectively in a mean median time of 12 months. The only patient variable affecting the prognosis was baseline extent of AA. Excellent response was seen in 100%, 77%, 54%, 50% and 41% in Grade 1, Grade 2, Grade 3, AA totalis and AA universalis patients respectively. Side-effects were few and tolerable. Hair fall >25% occurred in 17.9% of patients on maintenance and 57.1% of patients without maintenance therapy (P-value=0.025).
CONCLUSION: Diphencyprone is an effective and safe treatment of extensive AA. A long period of therapy is needed and will increase the percentage of responders especially in alopecia totalis and universalis. Maintenance therapy is recommended to reduce the risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744175     DOI: 10.1111/j.1468-3083.2009.03401.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

Review 1.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.

Authors:  Solam Lee; Beom Jun Kim; Young Bin Lee; Won-Soo Lee
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

3.  Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata.

Authors:  Yin-Ku Lin; Saleh A Al-Suwayeh; Yann-Lii Leu; Feng-Ming Shen; Jia-You Fang
Journal:  Pharm Res       Date:  2012-10-16       Impact factor: 4.200

4.  Topical immunotherapy in alopecia areata.

Authors:  Gurcharan Singh; Ms Lavanya
Journal:  Int J Trichology       Date:  2010-01

5.  Methotrexate in Alopecia Areata: A Report of Three Cases.

Authors:  Ana Batalla; Ángeles Flórez; Teresa Abalde; Hugo Vázquez-Veiga
Journal:  Int J Trichology       Date:  2016 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.